Literature DB >> 24659688

TLR4 ligands lipopolysaccharide and monophosphoryl lipid a differentially regulate effector and memory CD8+ T Cell differentiation.

Weiguo Cui1, Nikhil S Joshi, Ying Liu, Hailong Meng, Steven H Kleinstein, Susan M Kaech.   

Abstract

Vaccines formulated with nonreplicating pathogens require adjuvants to help bolster immunogenicity. The role of adjuvants in Ab production has been well studied, but how they influence memory CD8(+) T cell differentiation remains poorly defined. In this study we implemented dendritic cell-mediated immunization to study the effects of commonly used adjuvants, TLR ligands, on effector and memory CD8(+) T cell differentiation in mice. Intriguingly, we found that the TLR4 ligand LPS was far more superior to other TLR ligands in generating memory CD8(+) T cells upon immunization. LPS boosted clonal expansion similar to the other adjuvants, but fewer of the activated CD8(+) T cells died during contraction, generating a larger pool of memory cells. Surprisingly, monophosphoryl lipid A (MPLA), another TLR4 ligand, enhanced clonal expansion of effector CD8(+) T cells, but it also promoted their terminal differentiation and contraction; thus, fewer memory CD8(+) T cells formed, and MPLA-primed animals were less protected against secondary infection compared with those primed with LPS. Furthermore, gene expression profiling revealed that LPS-primed effector cells displayed a stronger pro-memory gene expression signature, whereas the gene expression profile of MPLA-primed effector cells aligned closer with terminal effector CD8(+) T cells. Lastly, we demonstrated that the LPS-TLR4-derived "pro-memory" signals were MyD88, but not Toll/IL-1R domain-containing adapter inducing IFN-β, dependent. This study reveals the influential power of adjuvants on the quantity and quality of CD8(+) T cell memory, and that attention to adjuvant selection is crucial because boosting effector cell expansion may not always equate with more memory T cells or greater protection.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24659688      PMCID: PMC4071140          DOI: 10.4049/jimmunol.1302569

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  60 in total

1.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository.

Authors:  Ron Edgar; Michael Domrachev; Alex E Lash
Journal:  Nucleic Acids Res       Date:  2002-01-01       Impact factor: 16.971

2.  Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells.

Authors:  Megan K L MacLeod; Amy S McKee; Alexandria David; Jieru Wang; Robert Mason; John W Kappler; Philippa Marrack
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

3.  Dendritic cell maturation triggers retrograde MHC class II transport from lysosomes to the plasma membrane.

Authors:  Amy Chow; Derek Toomre; Wendy Garrett; Ira Mellman
Journal:  Nature       Date:  2002-08-29       Impact factor: 49.962

4.  A framework for oligonucleotide microarray preprocessing.

Authors:  Benilton S Carvalho; Rafael A Irizarry
Journal:  Bioinformatics       Date:  2010-08-05       Impact factor: 6.937

5.  Impaired pulmonary NF-kappaB activation in response to lipopolysaccharide in NADPH oxidase-deficient mice.

Authors:  M A Koay; J W Christman; B H Segal; A Venkatakrishnan; T R Blackwell; S M Holland; T S Blackwell
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

6.  Intrinsic IL-21 signaling is critical for CD8 T cell survival and memory formation in response to vaccinia viral infection.

Authors:  Patricia Novy; Xiaopei Huang; Warren J Leonard; Yiping Yang
Journal:  J Immunol       Date:  2011-01-21       Impact factor: 5.422

7.  Plasmodium-host interactions directly influence the threshold of memory CD8 T cells required for protective immunity.

Authors:  Nathan W Schmidt; Noah S Butler; John T Harty
Journal:  J Immunol       Date:  2011-04-01       Impact factor: 5.422

8.  Programmed contraction of CD8(+) T cells after infection.

Authors:  Vladimir P Badovinac; Brandon B Porter; John T Harty
Journal:  Nat Immunol       Date:  2002-06-03       Impact factor: 25.606

Review 9.  Vaccine adjuvants: putting innate immunity to work.

Authors:  Robert L Coffman; Alan Sher; Robert A Seder
Journal:  Immunity       Date:  2010-10-29       Impact factor: 31.745

10.  Programming the magnitude and persistence of antibody responses with innate immunity.

Authors:  Sudhir Pai Kasturi; Ioanna Skountzou; Randy A Albrecht; Dimitrios Koutsonanos; Tang Hua; Helder I Nakaya; Rajesh Ravindran; Shelley Stewart; Munir Alam; Marcin Kwissa; Francois Villinger; Niren Murthy; John Steel; Joshy Jacob; Robert J Hogan; Adolfo García-Sastre; Richard Compans; Bali Pulendran
Journal:  Nature       Date:  2011-02-24       Impact factor: 49.962

View more
  28 in total

1.  Bordetella pertussis Lipid A Recognition by Toll-like Receptor 4 and MD-2 Is Dependent on Distinct Charged and Uncharged Interfaces.

Authors:  Nina Maeshima; Tara Evans-Atkinson; Adeline M Hajjar; Rachel C Fernandez
Journal:  J Biol Chem       Date:  2015-04-02       Impact factor: 5.157

2.  Optimal CD4 T cell priming after LPS-based adjuvanticity with CD134 costimulation relies on CXCL9 production.

Authors:  Paurvi Shinde; Wenhai Liu; Antoine Ménoret; Andrew D Luster; Anthony T Vella
Journal:  J Leukoc Biol       Date:  2017-04-21       Impact factor: 4.962

3.  Priming and Activation of Inflammasome by Canarypox Virus Vector ALVAC via the cGAS/IFI16-STING-Type I IFN Pathway and AIM2 Sensor.

Authors:  Fengliang Liu; Qingli Niu; Xiuzhen Fan; Connie Liu; Jie Zhang; Zhi Wei; Wei Hou; Thirumala-Devi Kanneganti; Merlin L Robb; Jerome H Kim; Nelson L Michael; Jiaren Sun; Lynn Soong; Haitao Hu
Journal:  J Immunol       Date:  2017-09-25       Impact factor: 5.422

4.  Production of IL-10 by CD4(+) regulatory T cells during the resolution of infection promotes the maturation of memory CD8(+) T cells.

Authors:  Brian J Laidlaw; Weiguo Cui; Robert A Amezquita; Simon M Gray; Tianxia Guan; Yisi Lu; Yasushi Kobayashi; Richard A Flavell; Steven H Kleinstein; Joe Craft; Susan M Kaech
Journal:  Nat Immunol       Date:  2015-07-06       Impact factor: 25.606

5.  Dysfunction of Circulating Polymorphonuclear Leukocytes and Monocytes in Ambulatory Cirrhotics Predicts Patient Outcome.

Authors:  Konstantina Sargenti; Åsa Johansson; Sara Bertilsson; Inger Mattsby-Baltzer; Daniel Klintman; Evangelos Kalaitzakis
Journal:  Dig Dis Sci       Date:  2016-03-24       Impact factor: 3.199

6.  Monophosphoryl lipid A-induced activation of plasmacytoid dendritic cells enhances the anti-cancer effects of anti-PD-L1 antibodies.

Authors:  Wei Zhang; Seong-Min Lim; Juyoung Hwang; Srinivasan Ramalingam; Myunghee Kim; Jun-O Jin
Journal:  Cancer Immunol Immunother       Date:  2020-09-09       Impact factor: 6.968

7.  Responses to LPS boost effector CD8 T-cell accumulation outside of signals 1 and 2.

Authors:  Wenhai Liu; Antoine Menoret; Anthony T Vella
Journal:  Cell Mol Immunol       Date:  2015-07-20       Impact factor: 11.530

8.  Characterization of Diabetogenic CD8+ T Cells: IMMUNE THERAPY WITH METABOLIC BLOCKADE.

Authors:  Justin W Garyu; Mohamed Uduman; Alex Stewart; Jinxiu Rui; Songyan Deng; Jared Shenson; Matt M Staron; Susan M Kaech; Steven H Kleinstein; Kevan C Herold
Journal:  J Biol Chem       Date:  2016-03-18       Impact factor: 5.157

9.  A lipid A-based TLR4 mimetic effectively adjuvants a Yersinia pestis rF-V1 subunit vaccine in a murine challenge model.

Authors:  Kelsey A Gregg; Erin Harberts; Francesca M Gardner; Mark R Pelletier; Corinne Cayatte; Li Yu; Michael P McCarthy; Jason D Marshall; Robert K Ernst
Journal:  Vaccine       Date:  2018-05-31       Impact factor: 3.641

10.  Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8+ T cells to enhance antitumor immunity.

Authors:  Rosmely Hernandez; Kevin H Toomer; Janika Põder; Alicia Santos Savio; Sunnie Hsiung; Thomas R Malek
Journal:  Cancer Immunol Immunother       Date:  2020-10-10       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.